- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02009826
Psychosis-Associated Neuroinflammation in Schizophrenia (PANS)
August 30, 2017 updated by: Dr Livia De Picker, Universiteit Antwerpen
Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects
Previous research has suggested central nervous system inflammatory activity to be critically involved in disease development and progression in schizophrenia, with a complex interplay of inflammatory mechanisms leading to the development of brain abnormalities and medical symptoms related to schizophrenia.
However, the mutual interactions of different inflammatory pathways and their relation to disease course have not been sufficiently studied.
This study therefore aims to explore the interaction of neuroinflammatory mechanisms in patients with schizophrenia and to assess whether the inflammatory activity in schizophrenia is state-dependent and occurs mainly during psychotic episodes.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
106
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Antwerp
-
Mortsel, Antwerp, Belgium, 2640
- Psychiatrisch Ziekenhuis Sint-Amedeus
-
-
Antwerpen
-
Boechout, Antwerpen, Belgium, 2530
- Psychiatrisch Ziekenhuis Broeders Alexianen
-
Duffel, Antwerpen, Belgium, 2570
- Psychiatrisch Ziekenhuis St Norbertus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Young schizophrenia patients admitted to psychiatric hospital for acute relapse or first-episode of psychosis
Description
Inclusion Criteria:
- Be a man or woman between 18 and 40 years of age, inclusive.
- Have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in this study.
- Be medically stable on the basis of physical examination and vital signs performed at Screening.
- Be medically stable on the basis of clinical laboratory tests performed at Screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study.
- Be willing and able to adhere to the prohibitions and restrictions specified in the protocol.
Schizophrenia subjects:
- Fulfill DSM-V criteria for the schizophrenia spectrum (DSM-V #295.1-295.6, 295.9, 298.9)
- Be admitted to hospital for first-episode psychosis or acute relapse of psychosis, as defined by:
total score of ≥14 on the positive scale of the "Positive and Negative Syndrome Scale" (PANSS) and at least a score of 5 on 1 item or a score of 4 on 2 "psychotic" PANSS items P2, P3, P5 or G9 at Screening.
Exclusion Criteria:
- Use of nonsteroidal antiinflammatory drugs, paracetamol, immunosuppressant or immunostimulating drugs within 21 days of screening.
- Use of systemic corticosteroids within 21 days of screening.
- Has a history of drug or alcohol dependence according to DSM-V criteria, except nicotine or caffeine, within 6 months before screening.
- Has history of (co-morbid) somatization or mood disorder according to DSM-V criteria within 6 months before screening.
- Has a positive test result for drugs of abuse or for alcohol at screening or test day.
- Female subjects only: is pregnant or breastfeeding
- Has a history of chronic or acute physical illness associated with abnormal immune changes within the 2 weeks before the study.
- Leukocytosis (i.e., white blood cell count ≤ 11 x109 /L) on screening and test days.
- Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV antibodies at screening.
- Has a medical history of any auto-immune disorder or chronic inflammatory disease.
- Has received electroconvulsive therapy in the last 6 months.
- Is currently enrolled in a study with an investigational study drug.
- Worsening or first time occurrence of significant suicidality
- Has donated blood within 3 months before screening.
- Has any condition that, in the opinion of the investigator, would compromise the wellbeing of the subject or the study or prevent the subject from meeting or performing study requirements.
- Low affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at Screening
- Use of benzodiazepines for 3x the half-life prior to PET-scan
- Presence of irremovable magnetic materials in or on the body
- Has a medical history of organic brain disease
- Has a medical history of traumatic brain injury
- Has a medical history of allergic reaction to any of the substances in the tracer fluid.
- Unwillingness or inability of subject to undergo PET and/or MRI scan (for example due to claustrophobia or lack of cooperation)
Healthy volunteers:
- Personal history of psychotic disorder
- Family history of psychotic or bipolar disorder in first-degree relatives
- Family history of auto-immune disorder in first-degree relatives
Schizophrenia patients:
- Calgary Depression Scale for Schizophrenia (CDSS) score >6 at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
Healthy age- and sex-matched controls
|
[18F]-PBR111 radioligand to assess binding to TSPO
Cognitive and psychomotor tasks on digitizing tablet
Blood sampling for peripheral inflammatory and neurotoxicity markers
|
Schizophrenia patients
Young schizophrenia patients 18-40y
|
[18F]-PBR111 radioligand to assess binding to TSPO
Cognitive and psychomotor tasks on digitizing tablet
Blood sampling for peripheral inflammatory and neurotoxicity markers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional VT of [18F]PBR111
Time Frame: 2 years
|
Regional distribution volume in tissue (VT) of 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (PBR111) labelled with fluorine-18 (18F) in schizophrenia patients and age- , gender-, and translocator protein (TSPO) binding profile- matched healthy controls
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral markers
Time Frame: 2 years
|
Levels and ratios of inflammatory and neurotoxicity markers in blood samples of schizophrenia patients compared to healthy age- and gender-matched healthy controls.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Bernard Sabbe, MD PhD, Universiteit Antwerpen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
February 1, 2017
Study Completion (Actual)
February 1, 2017
Study Registration Dates
First Submitted
December 9, 2013
First Submitted That Met QC Criteria
December 9, 2013
First Posted (Estimate)
December 12, 2013
Study Record Updates
Last Update Posted (Actual)
August 31, 2017
Last Update Submitted That Met QC Criteria
August 30, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPRI13/37/348
- B300201318710 (Other Identifier: Belgian Study Registration Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on [18F]-PBR111 Positron Emission Tomography (PET)
-
National Cancer Institute (NCI)TerminatedKidney Neoplasms | Carcinoma, Renal CellUnited States
-
National Cancer Institute (NCI)Completed
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitation
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Neil M Rofsky, MD, MHACompletedAlzheimer Disease | Cognitive DeclineUnited States
-
Stanford UniversityNational Cancer Institute (NCI)CompletedPancreatic Carcinoma | Healthy SubjectUnited States
-
M.D. Anderson Cancer CenterGE HealthcareWithdrawn
-
University Hospital, BordeauxRecruiting
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)RecruitingHead and Neck Squamous Cell Carcinoma | Brain MetastasesUnited States
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedMETASTATIC BREAST CANCERUnited States